Advanced Filters
noise
Found 811 clinical trials
A Anki MIU, MSc

CUHK Brain Health Longitudinal Study

The goal of this study is to develop a large longitudinal cohort of individuals diagnosed with or at high risk for brain diseases (both neurological and psychiatric in nature), in order to identify risk factors that contribute to neurological and psychiatric diseases over time. The investigators seek to capture relevant …

18 years of age All Phase N/A

Exploring the Diagnostic Biomarkers of Cognitive Disorders in China

Dementia is a syndrome characterized by progressive global cognitive impairment that impairs occupational, family, or social functioning. It detrimentally affects personal health and quality of life, imposing significant medical economy, social and psychological burden on the countries and the patients' family. The internationally renowned dementia cohort includes the DIAN that …

40 - 90 years of age All Phase N/A
j jianwen Guo, Dr

The Dampness Syndrome of Chinese Medicine Cohort Study

The researchers plain to build a large-scale, longitudinal, prospective cohort characterized by TCM dampness syndrome. With the biobank of this cohort the investigators want to find the causality between TCM dampness syndrome and clinical chronic diseases and a new way to treat clinical disease.

35 - 79 years of age All Phase N/A
Y Yi Tang, M.D., Ph.D.

China Healthy Aging Cohort Study

This is a community-based prospective cohort study in China. The study has been initialized in 2024 and included older residents. The goal of this observational study is to explore the risk factors related to disability and dementia in the elderly Chinese community population, and develop a risk prediction model for …

60 years of age All Phase N/A
E Erik Stomrud, MD, PhD

The Swedish BioFINDER 2 Study

The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in …

20 - 100 years of age All Phase N/A
Z Zhou Xinyu, Doctor of Philosophy

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

This project aims to investigate the effectiveness of existing common antidepressants and to provide new evidence for depressed children and adolescents who are not responding to their first treatment.

13 - 18 years of age All Phase 1/2
P Peiyuan Lv, Doctor

China Cognition and Aging Study

The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of dementia and its subtypes in China. It is of great significance to establish a …

18 years of age All Phase N/A
M Mayra Macias

TabCAT Brain Health Assessment in Primary Care

Efficient and user-friendly paradigms to detect cognitive impairment, including dementia are needed in primary care. The TabCAT Brain Health Assessment accurately detects cognitive impairment via an appealing tablet interface with automated scoring and EMR integration. This study will evaluate the effectiveness of the paradigm on detection rates and other brain …

18 years of age All Phase N/A
N NIA Studies Recruitment

Genetic Characterization of Movement Disorders and Dementias

Background There are two basic types of movement disorders. Some cause excessive movement, some cause slowness or lack of movement. Some of these are caused by mutations in genes. On the other hand, dementia is a condition of declining mental abilities, especially memory. Dementia can occur at any age but …

18 - 120 years of age All Phase N/A
C Cathy Cheney

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.

12 - 15 years of age All Phase N/A

Simplify language using AI